Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

In Silico Characterization of Masitinib Interaction with SARS-CoV-2 Main Protease.

ChemMedChem - 5 Aug 2021

Martínez-Ortega Ulises, Figueroa-Figueroa Diego I, Hernández-Luis Francisco, Aguayo-Ortiz Rodrigo

Abstract excerpt

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection continues to be a global health problem. Despite the current implementation of COVID-19 vaccination schedules, identifying effective antiviral drug treatments for this disease continues to be a priority. A recent study showed that masitinib (MST), a tyrosine kinase inhibitor, blocks the proteolytic activity of SARS-CoV-2 main protease (Mpro )....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Coronavirus 3C Proteases
Share to Cysteine Proteinase Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hydrogen Bonding

Share to Piperidines

Share to Pyridines

Share to Static Electricity

Share to Thiazoles

Source

Open in PubMed Open full text

Identifiers

PMID: 34142459
DOI: 10.1002/cmdc.202100375
PMCID: PMC8426933

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

In Silico Characterization of Masitinib Interaction with SARS-CoV-2 Main Protease.PMID 34142459Read ↗

Is PF-00835231 a Pan-SARS-CoV-2 Mpro Inhibitor? A Comparative StudySemantic proximity Read ↗

Structure-Based Virtual Screening to Discover Potential Lead Molecules for the SARS-CoV‑2 Main ProteaseSemantic proximity Read ↗

High Throughput Virtual Screening and Validation of a SARS-CoV-2 Main Protease Non-Covalent InhibitorSemantic proximity Read ↗

SARS-CoV-2 main protease (M-pro) mutational profiling: An insight into mutation coldspots.Semantic proximity Read ↗

Structural basis for the inhibition of coronaviral main proteases by PF-00835231.Semantic proximity Read ↗

Structural basis for the inhibition of coronaviral main proteases by PF-00835231Semantic proximity Read ↗

Structural Basis of the Main Proteases of Coronavirus Bound to Drug Candidate PF-07321332Semantic proximity Read ↗

Interaction of Drug Candidates with Various SARS-CoV‑2 Receptors: An in Silico Study to Combat COVID-19Semantic proximity Read ↗

Identification of mutation resistance coldspots for targeting the SARS-CoV2 main protease.Semantic proximity Read ↗

Inhibitory efficacy and structural insights of Bofutrelvir against SARS-CoV-2 Mpro mutants and MERS-CoV MproSemantic proximity Read ↗

Novel inhibitors against COVID-19 main protease suppressed viral infectionSemantic proximity Read ↗

Structural Differences In 3C-like protease (Mpro) From SARS-CoV and SARS-CoV-2: Molecular Insights For Drug Repurposing Against COVID-19 Revealed by Molecular Dynamics SimulationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.